# RASolute 302 (NCT06625320)

> Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06625320
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Revolution Medicines, Inc.
- Conditions: Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma
- Interventions: RMC-6236; Gemcitabine; nab-paclitaxel; Irinotecan; Liposomal irinotecan; 5-fluorouracil; leucovorin; Oxaliplatin
- Enrollment: 500
- Primary outcome: Progression free survival (PFS) in the RAS G12-mutant population
- Primary outcome: Overall survival (OS) in the RAS G12-mutant population

## Commentary we found

- X threads: 146
- YouTube: 42
- Podcasts: 38
- X videos: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rasolute-302-nct06625320

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06625320", "email": "<work email>"}; the inbox owner confirms by the emailed link.